Clinical Trial Update: PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]

View source ↗

Summary

PH009-1 is an investigational therapy for EGFR-mutated non-small cell lung cancer (locally advanced or metastatic), and the Phase 1/2 trial is currently not yet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PH009-1

Snippet

Sponsor: Suzhou Puhe Pharmaceutical Technology Co., LTD | Conditions: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING